Ibio, INC Schedule 13G passive stakes

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 5,068,882 shares of iBio, Inc. common stock, representing 9.99% of the outstanding shares.

Logos Global Management and associated entities have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in iBio, Inc.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in iBio, Inc. as of March 31, 2026.

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 4.6% beneficial ownership stake in iBio, Inc.

Cormorant Asset Management, LP and Bihua Chen have reported an increased beneficial ownership of iBio, Inc. common stock, reaching 9.99% through the exercise of warrants.

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 9.9% of iBio, Inc. common stock, primarily through warrants, subject to a 9.99% ownership blocker.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 9.99% of iBio, Inc.'s common stock as of March 31, 2026.

Frazier Life Sciences entities report a combined 5.7% beneficial ownership in iBio, Inc. common stock as of March 31, 2026.

Lynx1 Capital Management LP and Weston Nichols report 0% beneficial ownership in iBio, Inc. common stock.

Affinity Asset Advisors, LLC and Michael Cho have disclosed a 9.99% beneficial ownership stake in iBio, Inc., including shares from warrants and a recent private placement.

Integrated Core Strategies, Millennium Management, Millennium Group Management, and Israel A. Englander have jointly reported a 5.2% beneficial ownership stake in iBio, Inc. common stock.

Logos Global Management LP and its affiliates have reported a passive beneficial ownership of 8.9% of iBio, Inc.'s common stock.

EcoR1 Capital, LLC and its principal Oleg Nodelman have disclosed a 9.9% beneficial ownership stake in iBio, Inc. common stock.

Frazier Life Sciences Public Fund, L.P. and its affiliates have reported a beneficial ownership of 8.7% in iBio, Inc.'s common stock.

Affinity Asset Advisors and Affinity Healthcare Fund have amended their Schedule 13G filing, disclosing a 9.99% beneficial ownership in iBio, Inc. common stock, primarily through warrants.

Ikarian Capital, LLC and Neil Shahrestani have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in IBIO, Inc.'s common stock.

Vestal Point Capital, LP and Ryan Wilder have reported a 9.9% beneficial ownership stake in iBio, Inc., primarily through warrants.

SilverArc Capital Management, LLC and Devesh Gandhi have reported a 9.99% beneficial ownership stake in iBio, Inc.'s Class A Common Stock.

Cormorant Asset Management and Bihua Chen have disclosed a 9.99% beneficial ownership stake in iBio, Inc., primarily through warrants.

Adage Capital Management, L.P. and its principals reported a 9.99% beneficial ownership stake in iBio, Inc., primarily through warrants.

Affinity Healthcare Fund and Affinity Asset Advisors have disclosed a 9.99% passive beneficial ownership stake in iBio, Inc., primarily through warrants.

Point72 Asset Management, along with affiliates and Steven A. Cohen, has disclosed a 9.9% beneficial ownership stake in iBio, Inc., primarily through warrants.

ADAR1 Capital Management and its affiliates report a 9.9% beneficial ownership stake in iBio, Inc., primarily through common stock and milestone warrants.

Patrick J. Crutcher has filed an Amendment to Schedule 13G, indicating a reduction in beneficial ownership of IBIO, Inc. common stock to 3.1%, triggering an exit filing.

ADAR1 Capital Management, along with its general partner and manager Daniel Schneeberger, has disclosed a 9.99% beneficial ownership stake in iBio, Inc., primarily through milestone warrants, as of December 31, 2024.

Opaleye Management, Inc. has filed an amended Schedule 13G, revealing a 7.6% beneficial ownership stake in iBio, Inc. as of December 31, 2024.

Patrick J. Crutcher has amended his Schedule 13G filing for IBIO, Inc., disclosing a beneficial ownership of 7.0% of common stock, totaling 696,713 shares, stemming from a licensing agreement, private placement, and consulting options.

Patrick J. Crutcher, CEO and majority shareholder of AstralBio, Inc., has reported a 7.2% beneficial ownership stake in IBIO, Inc., primarily through shares issued in connection with an exclusive licensing agreement and prior private placements.

Sabby Management, LLC, Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz have jointly reported a beneficial ownership of 0.21% in iBio, Inc.'s common stock as of December 31, 2024.